Article Details
Retrieved on: 2021-05-12 15:11:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Vyndaqel, for a rare heart condition, ATTR-CM, generated $429 million for Pfizer last year, following its launch in 2019. But it won't become available ...
Article found on: www.fiercepharma.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here